From: Winston-Salem Journal
***
Dr. Michael Siegel, a professor at the Boston University School of Public Health, expressed concern that the FDA’s goal with the pathway requirement will drive most small businesses, vape shops and e-cigarette companies out of business due to the high regulatory cost combined with a lack of resources and scientific expertise.
“It might be the case that not even the largest manufacturers – such as the tobacco companies – could be able to technically complete a successful application under the FDA deeming regulations and guidance,” Siegel said.